Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-30
2006-05-30
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S277000
Reexamination Certificate
active
07053097
ABSTRACT:
Compounds of formula 1:whereinR1is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0–3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;R2is hydroxy, amino, or lower alkoxy;R3is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl;R4is H or lower alkyl;and pharmaceutically acceptable salts and esters thereof;are effective inhibitors of GSK3.
REFERENCES:
patent: 5837853 (1998-11-01), Takashima et al.
patent: 5866702 (1999-02-01), Mackman et al.
patent: 6153618 (2000-11-01), Schultz
patent: 6767906 (2004-07-01), Imbach et al.
patent: 616032 (1994-09-01), None
patent: WO 97/16452 (1997-05-01), None
patent: WO 97/22360 (1997-06-01), None
patent: WO 97/41854 (1997-11-01), None
patent: WO-97-16452 (1998-05-01), None
Pelech, Neurobiology of Aging vol. 16(3) 247, 1995.
Imahori, J. Biochem. 121, 179(1997.
Briscoe, Current Biology 5(3) 228 (1995).
Welsh, Trends in Cell Biology 6(7) 274 (1996).
Anderton et al., “Modulation of PHF-Like Tau Phosphorylation in Cultured Neurones and Transfected Cells,”Neurobiology of Aging 16(3):389-402, 1995.
Borthwick et al., “Inhibition of Glycogen Synthase Kinase-3 by Insulin in Cultured Human Skeletal Muscle Myoblasts,”Biochemical and Biophysical Research Communications 210(3):738-745, May 25, 1995.
Briscoe et al., “A Kinases for Cell-Fate Determination?”Current Biology 5(3):228-231, 1995.
Havlicek et al., “Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors: Synthesis and cdc2 Inhibitory Activity of Olomoucine and Related Compounds,”J. Med. Chem. 40:408-412, 1997.
Imahori et al., “Physiology and Pathology of Tau Protein Kinases in Relation to Alzheimer's Disease,”J. Biochem. 121(2):179-188, 1997.
Klein and Melton, “A Molecular Mechanism for the Effect of Lithium on Development,”Proc. Natl. Acad. Sci. USA 93:8455-8459, Aug. 1996.
Latimer et al., “Stimulation of MAP Kinase by v-raf Transformation of Fibroblasts Fails to Induce Hyperphosphorylation of Transfected Tau,”FEBS Letters 365:42-46, 1995.
Lovestone et al., “Alzheimer's Disease-Like Phosphorylation of the Microtubule-Associated Protein Tau by Glycogen Synthase Kinase-3 in Transfected Mammalian Cells,”Current Biology 4(12):1077-1086, 1994.
Massillon et al., “Identification of the Glycogenic Compound 5-Iodotubercidin as a General Protein Kinase Inhibitor,”Biochem. J. 299:123-128, 1994.
Normon et al., “A Structure-Based Library Approach to Kinase Inhibitors,”J. Am. Chem. Soc. 118:7430-7431, 1966.
Pelech, “Networking With Proline-Directed Protein Kinases Implicated in Tau Phosphorylation,”Neurobiology of Aging 16(3):247-256, 1995.
Saran, “Antidiabetic Effects of Lithium,”J. Clin. Psychiatry 43(9):383-384, Sep. 1982.
Sperber et al., “Glycogen Synthase Kinase-3β Phosphorylates Tau Protein at Multiple Sites in Intact Cells,”Neuroscience Letters 197:149-153, 1995.
Stambolic et al., “Lithium Inhibits Glycogen Synthase Kinasae-3 Activity and Mimics Wingless Signalling in Intact Cells,”Current Biology 6(12):1664-1668, 1996.
Sutherland et al., “Inactivation of Glycogen Synthase Kinase-3β by Phosphorylation: New Kinase Connections in Insulin and Growth-Factor Signaling,”Biochem. J. 296:15-19, 1993.
Takashima et al., “Amyloid β Peptide Induces Cytoplasmic Accumulation of Amyloid Protein Precursor via Tau Protein Kinase I/glycogen Synthase Kinase-3β in Rat Hippocampal Neurons,”Neuroscience Letters 198:83-86, 1995.
Takashima et al., “Exposure of Rat Hippocampal Neurons to Amyloid β Peptide (25-35) Induces the Inactivation of Phosphatidyl Inositol-3 Kinase and the Activation of Tau Protein Kinase I/glycogen Synthase Kinase-3β,”Neuroscience Letters 203:33-36, 1996.
Takashima et al., “Tau Protein Kinase I Is Essential for Amyloid β-Protein-Induced Neurotoxicity,”Proc. Natl. Acad. Sci. USA 90:7789-7793, Aug. 1993.
Veselý et al., “Inhibition of Cyclin-Dependent Kinases by Purine Analogs,”Eur. J. Biochem. 224771-786, 1994.
Welsh et al., “GSK3: a SHAGGY frog story,”Trends in Cell Biology 6(7):274-279, 1996.
Bray Andrew M.
Harrison Stephen D.
Ring David B.
Schultz Peter
Berch Mark L.
Chiron Corporation
Harbin Alisa A.
Shelton Dennis K.
Suh Young J.
LandOfFree
Inhibitors of glycogen synthase 3 kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of glycogen synthase 3 kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of glycogen synthase 3 kinase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3529572